缺氧诱导因子脯氨酰羟化酶抑制剂在慢性肾脏病血管钙化中的研究进展

Research progress of hypoxia-nducible factor-prolyl hydroxylase inhibitor in vascular calcification in chronic kidney disease

缺氧诱导因子脯氨酰羟化酶抑制剂(HIF-PHI)是治疗慢性肾脏病(CKD)肾性贫血的新型药物。HIF-PHI作为缺氧诱导因子(HIF)稳定剂,可提高HIF表达水平,HIF的持续升高促进血管平滑肌细胞的成骨转分化和钙化,加大血管钙化的风险,长期使用HIF-PHI可能存在血管钙化的潜在风险。血管钙化是CKD患者心血管事件发病率和病死率增加的主要危险因素,因此应充分了解HIF-PHI潜在的危害性并加以重视。该文就HIF-PHI在CKD血管钙化中的研究进展进行综述。

Hypoxia-inducible factor-prolyl hydroxylase inhibitor(HIF-PHI)is a novel drug for treating renal anemia in chronic kidney disease(CKD).As a stabilizer of hypoxia-inducible factor(HIF),HIF-PHI can increase the expression level of HIF,and the continuous increase of HIF can promote the osteogenic transdifferentiation and calci-fication of vascular smooth muscle cells,which has the risk of increasing vascular calcification.Long-term use of HIF-PHI may have the potential risk of vascular calcification.Vascular calcification is a major risk factor for the increase of inci-dence rate and mortality rate of cardiovascular events in CKD patients.Therefore,the potential hazards of HIF-PHI should be fully understood and taken seriously.This paper reviews the research progress of HIF-PHI in vascular calcification in CKD.